Unfortunately, there are only a few systemic immunomodulatory biologic therapies approved for AD: Dupilumab (monoclonal antibody blocking IL-4 and IL-13) and Tralokilumab (human monoclonal antibody blocking IL-13). Here, IL13 is linked to Alzheimer disease.